Effect of locally delivered adjunctive antibiotics during surgical periodontal therapy: a systematic review and meta-analysis

Sarah Yusri 1 · Ahmed Elfana 1 · Weam Elbattawy 1 · Karim M Fawzy El-Sayed 1,2

Received: 9 May 2021 / Accepted: 27 June 2021 / Published online: 20 July 2021
© The Author(s) 2021

Abstract
Aim The present study aimed to systematically assess current evidence on effects of locally delivered antibiotics during periodontal surgery compared to periodontal surgery alone on clinical attachment level (CAL) gain, probing pocket depth (PPD) reduction, recession depth (RD) changes, gingival index (GI), bleeding on probing (BOP), and plaque index (PI).

Methodology MEDLINE-PubMed, Cochrane-CENTRAL and Scopus databases were searched up to April 2021 for randomized clinical trials (RCT), evaluating effects of locally delivered antibiotics during periodontal surgery. CAL gain served as primary, while PPD reduction, RD changes, GI and PI as secondary outcomes. The Cochrane Risk of Bias Tool was used to assess possible bias. Data were extracted, and meta-analysis was performed where appropriate.

Result Screening of 2314 papers resulted in nine eligible studies. No adverse events were reported. Data on outcome variables were pooled and analyzed using generic inverse variance model and presented as weighted mean difference (WMD) and 95% confidence interval (95% CI). Statistically significant improvements in favor of antibiotics’ delivery were observed in studies with follow-up of ≤6 months for CAL gain (WMD = 0.61 mm (95% CI [0.07, 1.14]; p = 0.03), PPD reduction (WMD = 0.41 mm (95% CI [0.02, 0.80]; p = 0.04)) and BOP (WMD = −28.47% (95% CI [−33.00, −23.94]; p < 0.001), while for GI improvements were notable for >6 to 12 months (WMD = −0.27 (95% CI [−0.49, −0.06]; p = 0.01)).

Conclusion Within the current review’s limitations, locally delivered antibiotics during surgical periodontal therapy results in post-surgical improvements for CAL, PPD, and BOP (≤6 months) with a longer-lasting GI improvement. Further randomized controlled trials are needed with true periodontal end-points to assess the ideal antibiotic agent, dosage, and delivery methods.

Clinical relevance Local delivery of antibiotics during periodontal surgery improved clinical parameters for up to 6-month follow-up, with beneficial longer effects on gingival inflammation. Within the current study’s limitation, the presented evidence could support the elective usage of locally delivered antibiotics during surgical periodontal therapy.

Keywords Local · Anti-bacterial · Antibiotics · Surgical · Periodontal therapy · Systematic review

Introduction
Periodontitis is an inflammatory destructive disorder of the tooth-supporting and -investing structures, associated with microbial dysbiosis [1]. Reversing periodontitis-associated dysbiosis is one of the primary strategies of periodontal therapy, comprising clinical strategies, implying the improvement of patients’ self-performed oral hygiene [2], in combination with professional mechanical debridement [3, 4] and in selective clinical conditions the application of adjunctive antimicrobial agents, systemically [5–7] or locally [8, 9]. Compared to systemic antibiotic application, local delivery demonstrates lower incidence of side effects, improved compliance, with lesser chances for emergence of microbial resistance [9, 10].

Although professional non-surgical periodontal debridement remains the cornerstone of successful periodontal therapy, certain clinical conditions may necessitate the application of surgical approaches [11, 12]. In this context, a controversy exists regarding a possible effect of adjunctive systemic antimicrobials combined with subgingival plaque control on
healing conditions and subsequent clinical outcomes of surgical periodontal therapy [13, 14]. Despite the possible benefits of locally delivered antibiotics in conjunction with surgical periodontal therapy, currently no clear evidence exists for their usage.

Thus, the objective of the present study was to systematically compile and analyze data from human studies on locally delivered adjunctive antibiotic therapy during periodontal surgery. The focused PICOS question was: Based on randomized controlled clinical trials (RCTs) on humans, what is the effect of locally delivered adjunctive anti-bacterial therapy during periodontal flap surgery, treating periodontitis-induced defects, compared to periodontal surgery alone, on clinical attachment level (CAL; primary outcome) gain, the probing pocket depth (PPD) reduction, the gingival recession depth (RD) changes, bleeding on probing (BOP), gingival index (GI), plaque index (PI) and radiographic changes (secondary outcomes)? We further aimed to perform a meta-analysis for the findings from different studies and to appraise their validity and applicability.

Materials and methods

Protocol registration and focused question

The protocol of this review article was pre-registered at the Prospective Register of Systematic Reviews (PROSPERO) on the 16th of February 2021 (CRD42021227099). This systematic review was conducted in accordance with the Cochrane handbook for systematic reviews of interventions [15] and reported in accordance with “Preferred Reporting Items for Systematic Review and Meta-Analysis” (PRISMA) guidelines [16]. The review aimed to answer the following question: During surgical intervention for treatment of periodontal diseases, will locally delivered antibiotics yield superior effects compared to periodontal surgery alone?

Search strategy

Primary search was conducted in electronic sources of the National Library of Medicine (MEDLINE via PubMed), the Cochrane Central Register of Controlled Trials (CENTRAL), and Scopus. Other sources for search included clinical trials registry (http://www.clinicaltrials.gov/) and grey literature sources (Open-grey: http://www.opengrey.eu/; Grey literature report: http://www.greylit.org/). Reference lists of initially selected studies were hand-searched for further published work that could meet the eligibility criteria. In addition a forward search of the citing literature reported in Google scholar citation report was conducted. The search was conducted up to the 15th of April 2021. The search strategy employed an approach, joining keywords for local antibiotics with keywords for periodontal surgery (Appendix 1), without language restriction.

Screening and selection

All entries from search databases were pooled into a single list and duplicates were removed (Endnote X9, Clarivate Analytics, USA), then exported to Rayyan online tool [17]. Two authors (SY, AE) independently conducted the initial screening of titles and abstracts, according to the eligibility criteria. Studies were selected for further reading if their title and/or abstract presented suitability to eligibility aspects. Disagreement between the two reviewers was resolved after additional discussion, and if it persisted, judgment by a third author (KFE) was conclusive. After initial selection, full-text papers were read in detail (SY, AE) and in case of unresolved disagreement, arbitration was sought after (KFE). Reasons for articles’ exclusion were recorded, and papers that fulfilled all selection criteria were processed for data collection. Cohen’s kappa coefficient was used to calculate agreement between authors [18].

The following eligibility criteria were employed:

(I) Study design: Randomized controlled clinical trials (RCTs) applying locally delivered antibiotics during periodontal flap surgery, treating periodontitis-induced defects. Studies should have quantitatively appraised one or more of the predefined outcomes (see below).

(II) Population: Adult participants diagnosed with periodontitis and undergoing periodontal surgery.

(III) Intervention: Surgical periodontal intervention of sites with PPD ≥ 5 mm in conjunction with locally delivered antibiotics into the surgical defects at the time of surgery.

(IV) Control: Surgical periodontal intervention without locally delivered antibiotics.

(V) Outcomes: Seven outcomes were assessed: CAL gain (the distance measured from the cementoenamel junction (CEJ) to the depth of the periodontal pocket; primary outcome), PPD reduction (the distance measured from the free gingival margin to the depth of the periodontal pocket), RD changes (the distance measured from the CEJ to the free gingival margin), BOP [19], GI, and PI [20], and radiographic changes (secondary outcomes).

The following was set as exclusion criteria:

- Studies with unbalanced interventions and controls (e.g., applying bone grafts with antibiotics in the test-group and no bone graft nor antibiotics applied in the control-
group). Standard delivery vehicles of antibiotics (e.g., methylcellulose, carboxymethyl cellulose, carboxyethyl cellulose, polypropylene) were exempted.

- Studies on smokers and diabetic patients
- Non-periodontitis conditions (e.g., peri-implantitis, muco-gingival correction, extraction sockets)
- Studies reporting the use of pre-operative or post-operative systemic antibiotics
- Antibiotics used as topical application/mouthwash and not delivered directly into the surgical site
- Antibiotics used transiently during the surgery for root conditioning and/or rinsed after application prior to flap closure

**Quality assessment**

The quality of the included studies was assessed using the Cochrane Risk of Bias Tool for randomized clinical trials (RoB 2, updated in 2019) [21] by AE and SY. Each study was judged as at low risk, high risk, or reflecting some concerns according to the following domains:

1. Randomization process: Allocation sequence generation, allocation concealment, and implementation
2. Deviations from intended interventions: Assessing both effect of assignment to intervention and effect of adhering to intervention
3. Missing outcome data: Availability of data for all or nearly all participants
4. Measurement of the outcome: Assessing method of measurement and whether prior knowledge of assigned group would influence outcome data.
5. Selection of the reported result: Data analysis is in accordance with pre-specified study plan.

For each study, the overall judgment was low risk in case of achieving low risk in all domains, unclear risk in case one or more domains demonstrated unclear risk, and high risk of bias when having at least one high risk domain or multiple unclear risk domains.

**Data extraction and study characteristics assessment**

All included studies went through relevant data extraction through standardized pre-defined data extraction sheets (AE) and cross-checked independently by another author (SY). Data of interest were study design, number of defects/participants in each arm, study setting, the treated periodontal condition, type of interventions, type, form, and concentration of antibiotics used, follow-up intervals, reported systemic antibiotic embargo period, in addition to the pre-defined primary and secondary outcomes on basis of intention-to-treat analyses [22]. Authors were contacted for papers with missing data (AE).

**Quantitative synthesis**

Studies were initially summarized for main characteristics and types of outcomes measured. Choice to pool results into meta-analysis was taken when two or more studies presented the same measured outcome. Outcomes’ data were recorded on patient’s level and were grouped into two effect durations: up to 6 months (≤6 months) and longer than 6 months (>6 to 12 months) [23, 24]. If the SD of the mean difference could not be retrieved it was imputed, using the Follmann method [25] from baseline and final values data, and an average correlation calculated from included studies [26]. In case this was not feasible, the average of other studies’ SD in the respective group was used [27]. For split-mouth studies, outcomes data were pooled, taking into account the within-person correlation by using results from paired tests or calculated from individual patients data (IPD) and if not available, SD was imputed with relevant correlation [26]. Summary of data synthesis is presented in Appendix 2.

The meta-analyses were conducted when feasible with the inverse variance model using Review Manager (RevMan, Version 5.4.1, The Cochrane Collaboration, 2020). Sub-analyses were performed on the observation periods up to 6 months and more than 6 months of follow-ups. Weighted averages of treatment effects across studies were calculated, using the random-effect model. In cases where the estimate of between-study variance was poor, as a result of low number of pooled studies (when four or fewer studies were included) the fixed-effect analysis was used [28]. Forest plots were generated to visually present the treatment effects using weighted mean difference (WMD) and 95% confidence interval (95% CI) and statistical significance cutoff was set at p < 0.05.

**Assessment of heterogeneity**

Heterogeneity was assessed statistically using Cochran’s Q and I²-statistics [29], and interpreted as low heterogeneity for $I^2 = 0–40\%$, moderate for $I^2 = 30–60\%$, substantial for $I^2 = 50–90\%$ and considerable for $I^2 = 75–100\%$ [30]. Publication bias was planned to be investigated with funnel plot and Egger regression intercept test [31], in case of 10 or more included studies in a meta-analysis. Sensitivity analyses were carried out assuming within-person correlation of 0, being the most conservative estimate [26], in addition to catering for variations in study designs (split-mouth and parallel groups).
Strength of the evidence

The Grading of Recommendations Assessment, Development and Evaluation (GRADE) is a system to grade evidence quality and recommendation strength for data on a specific intervention [32]. The strength of evidence for the primary outcome (CAL gain) at follow-up >6 to 12 months was presented using the GRADE approach for grading the quality of evidence and the strength of our recommendations into very low, low, moderate, or high levels of evidence quality/certainty.

Results

Literature search results

The online search yielded 1011 records in MEDLINE, 573 in Cochrane, 1491 in Scopus and four records were retrieved from other sources. After duplicate removal, a total of 2314 articles were screened for title and abstract, out of which 32 articles were selected for full text assessment (agreement \( k = 0.63 \)). Thereafter, 23 articles were excluded (Figure 1; Appendix 3) and nine articles were included in this review (agreement \( k = 0.57 \)).

Included studies’ characteristics

Regarding the included RCTs, two studies had parallel groups [33, 34], while seven employed a split-mouth design [35–41]. Overall, the number of participants in the included data ranged from nine to 30 individuals per group and with a follow-up period ranging between 3 and 12 months. All studies randomized participants to the treatment groups, with blinding being reported only in five studies [33, 34, 36, 37, 39]. Investigations were conducted under university settings except in three studies where it was not reported [34, 38, 39]. Except for a single investigation [41], all studies reported no previous antibiotic use for the participants for the last 3 [34, 37, 38], 6 months [33, 39, 40], or generally [35, 36].

The periodontal condition requiring surgical treatment was defined as PPD \( \geq 6 \) mm in five studies [34–37, 39], PPD>6 mm [40], PPD>5 mm [38], having a mandibular furcation grade-II defects [33], or PPD ranging from 5 to 7 mm [41]. All studies reported the implementation of non-surgical periodontal therapy pre-operatively. Regarding the surgical interventions for osseous defect therapy, different approaches were employed, including open flap debridement (OFD) [35, 37], OFD with platelet-rich fibrin [41], modified Widman flap [34], guided tissue regeneration (GTR) using membrane [36, 40], GTR using membrane and bone graft [33] or bone grafts only [38, 39]. The most frequently locally delivered antibiotic agent was Metronidazole [34, 36, 40, 41], followed by Minocycline [35, 37], Doxycycline [33], Tetracycline [38], and Moxifloxacin [39]. Studies’ characteristics are summarized in Table 1.

Adverse effects and patient-reported outcomes during healing

None of the studies reported any adverse effects linked to antibiotic usage, with uneventful healing observed. A study reported that one participant experienced pain in site with antibiotic administration, while five other participants demonstrated pain and unpleasant taste in the control sites 1 week post-operatively, with no differences observed in healing [36]. The same study further reported that one of the treated-furcation defects of the control-group failed to close at the end of the follow-up period, and the tooth was deemed for extraction.

Quality assessment

Out of the nine included studies, three studies (33%) were judged to have low risk of bias, five (56%) to show unclear risk, and one (11%) with high risk of bias. The most frequent source of bias was related to randomization (only 44% having low risk of bias), followed by bias in outcome measurement (56% with low risk of bias) (Figure 2).

Meta-analysis (Figure 3)

CAL gain

Seven studies reported CAL gain on follow-up \( \leq 6 \) months [35–41]. The antibiotic-group showed a statistically significant higher WMD CAL gain of 0.61 mm (95% CI [0.07, 1.14]; \( p = 0.03 \)). Heterogeneity was considerable (\( I^2 = 89\% \); \( p < 0.001 \)). For effect at follow-up of >6 to 12 months, five studies reported CAL gain [33, 34, 38, 39, 41], with a statistically non-significant WMD of 0.41 mm (95% CI [−0.24,1.06]; \( p = 0.22 \)) favoring the antibiotic-group, and substantial heterogeneity (\( I^2 = 69\% \); \( p = 0.01 \)). Sensitivity analysis could not explain heterogeneity based on variation in study design and analysis assuming a within-participant correlation \( r = 0 \) only made a negligible difference to the overall estimate (Appendix 4).

PPD reduction

For PPD reduction, seven [35–41] and five studies [33, 34, 38, 39, 41] were included in the \( \leq 6 \) months and >6 to 12 months of follow-ups’ pooled data analysis respectively. For the follow-up of \( \leq 6 \) months, the antibiotic-group showed a statistically significant higher WMD PPD reduction of 0.41 mm (95% CI [0.02, 0.80]; \( p = 0.04 \)). Heterogeneity was...
considerable ($I^2 = 87\% ; p < 0.001$). For follow-up of >6 to 12 months, a statistically non-significant WMD of 0.32 mm (95% CI $[-0.09, 0.73]$; $p = 0.13$) favored the antibiotic-group, and heterogeneity was moderate ($I^2 = 41\% ; p = 0.15$). Sensitivity analysis could not explain heterogeneity based on the study design, and analysis with correlation $r = 0$ only made a negligible difference to the overall estimate (Appendix 4).

**RD changes**

RD changes for follow-up of $\leq 6$ months were reported in two studies [37, 38], while longer follow-up (>6 to 12 months) data were reported in two studies [33, 38]. WMD showed a non-significant difference regarding RD changes in both analyses, 0.16 mm (95% CI $[-0.29, 0.62]$; $p = 0.48$) and 0.08 mm (95% CI $[-0.62, 0.78]$; $p = 0.83$) respectively. Heterogeneity was low ($I^2 = 0\% ; p = 0.82$) and moderate ($I^2 = 44\% ; p = 0.18$) respectively.

**GI**

Two studies reported GI scores for follow-up at $\leq 6$ months [36, 41], with the antibiotic-group showing lower GI scores with a WMD of $-0.09$ (95% CI $[-0.13, -0.04]$; $p < 0.001$) and considerable heterogeneity ($I^2 = 90\% ; p = 0.002$). In addition, two studies reported GI-data for longer (>6 to 12 months) follow-up [33, 41], and the WMD of $-0.27$ (95% CI $[-0.49, -0.06]$; $p = 0.01$) was significantly lower in the antibiotic-group with low heterogeneity ($I^2 = 0\% ; p = 0.77$).
| Study                | Study design/randomization/blinding | Number of participants | Age       | Gender (male/female) | Periodontal condition | Interventions (concentration) | Antibiotic type | Delivery method | Duration of follow-up | Study setting | Previous antibiotic use |
|---------------------|------------------------------------|------------------------|-----------|----------------------|------------------------|--------------------------|----------------|----------------|-----------------------|---------------|------------------------|
| Abbas et al. [35]   | Split-mouth/yes/not reported        | 30                     | 30–50     | Not mentioned         | PPD ≥ 6 mm, generalized chronic periodontitis | OFD with/without antibiotic | Minocycline 1 mg (2%) | Periofeel dental ointment | 6 months*  | University            | No previous antibiotic use |
| Dowell et al. [36]  | Split-mouth/yes/yes                | 16                     | 43.7 ± 0.4| 7/9                  | PPD ≥ 6 mm and evidence of radiographic bone loss | GTR (membrane) with/without antibiotic | Metronidazole, 8 mg per 1 cm² | Collagen membrane | 26 weeks   | University            | No previous antibiotic use |
| Jung et al. [37]    | Split-mouth/yes/yes                | 20                     | 43–69     | 14/6                 | At least 6 mm deep accompanying BOP. Chronic severe periodontitis | OFD with/without antibiotic | Minocycline 1 mg (2%) | Periocline ointment | 6 months*  | University            | No previous antibiotic use in last 3 months |
| Lyons et al. [33]   | Parallel/yes/yes                   | 18                     | 43–67     |                      | Moderate or severe chronic periodontitis and a mandibular molar with a buccal or lingual degree-II furcation defect | GTR (bone + membrane) with/without antibiotic | 4% doxycycline hyclate | Poly (DL-lactide) PLA barrier | 9 months   | University            | No previous antibiotic use in last 6 months |
| Masters et al. [38] | Split-mouth/yes/not reported        | 15                     | 35–61     | 3/12                 | PPD ≥ 5 mm and radiographic evidence of an intrabony defect in patients with advanced adult periodontitis | Bone graft with/without antibiotic | Tetracycline hydrochloride, 50 mg/ml solution | DFDBA | 12 months   | Not mentioned         | No systemic tetracycline or metronidazole therapy within 3 months of the surgery |
| Needleman et al. [34] | Parallel/yes/yes                  | 38                     | 35–65     | Not mentioned        | PPD ≥ 6 mm with BOP, evidence of radiographic bone loss in moderate to advanced periodontitis | MWF surgery with/without antibiotic | 25% metronidazole | Elyzol Dental Gel | 12 months   | Not mentioned         | No systemic or local antimicrobial therapy in the previous 3 months |
| Reddy et al. [39]   | Split-mouth/yes/yes                | 15                     | Not mentioned | Not mentioned | PPD of ≥ 6 mm, with radiographic evidence of vertical/angular defects. Chronic generalized periodontitis | Bone graft with/without antibiotic | Moxifloxacin 0.4% | Gel with inert matrix then mixed with hydroxyapatite composite graft | 12 months   | Not mentioned         | Not taken antibiotics within last 6 months |
| Sander et al. [40]  | Split-mouth/yes/not reported        | 12                     | 20–60     | 5/7                  | PPD > 6 mm and evidence of | GTR (membrane) | Paroject gel | 6 months   | University            | No systemic antibiotics 6 |
Two studies reported BOP scores for the follow-up at ≤6 months [35, 37]. The WMD of BOP scores were $-28.47\%$ (95% CI $[-33.00, -23.94]$), significantly favoring the antibiotic-group ($p < 0.001$) with low heterogeneity ($I^2 = 0\%; p = 0.83$). Needleman et al., 2000 [34] reported that three out of 18 sites in the antibiotic-group while four of 20 sites in the control-group showed BOP. Sander et al., 1994 [40] reported that none of the surfaces in the antibiotic-group showed BOP at the follow-up, but 8.3% of the surfaces in the control-group had BOP. Due to the difference in outcome reporting the two latter studies were not included in the meta-analysis.

**PI**

Four studies reported PI-data for follow-up at ≤6 months [35–37, 41]; with a non-significant WMD of $-0.03$ (95% CI $[-0.09, 0.03]$; $p = 0.35$) and moderate heterogeneity ($I^2 = 52\%; p = 0.10$). Two further studies reported PI for >6 to 12 months of follow-up [33, 41] with a non-significantly lower WMD of $-0.13$ (95% CI $[-0.37, 0.11]$; $p = 0.29$) in the antibiotic-group and moderate heterogeneity ($I^2 = 54\%; p = 0.14$). Data from the study of Sander et al., 1994 [40] could not be included in the calculation since it only reported the percentage of surfaces showing plaque scores 2 or 3. Similarly, data from Needleman et al., 2000 reported plaque as a dichotomous outcome (yes/no: 2/18 sites in test and 6/20 sites in control) and could not be included in the meta-analysis.

**Radiographic changes**

Three studies reported radiographic outcomes, but meta-analysis was not feasible due to heterogeneity in outcome measurements. In one study [38], radiographic density values were comparable in both antibiotic- and control-groups. In the second study [39], the percentage of radiographic defect fill revealed a statistically non-significant difference, where the antibiotic-group demonstrated a fill of 31.47 ± 6.46% while the control-group 29.15 ± 6.33%. Finally, the mean radiographic increase in alveolar bone height was significantly higher in the antibiotic-group, showing a median increase of 39%, compared to 28% in the control-group in the third study [40].

**Grading the “body of evidence”**

Table 2 shows the summary for various criteria used to assess the quality of evidence for the pooled estimate for CAL gain on follow-up for >6 to 12 months. Overall, evidence was rated as “very low”, being downgraded for including studies with some concerns or high risk of bias (67% of included studies),
for inconsistency due to unexplained heterogeneity, and for imprecision of the treatment effect.

Discussion

Due to the remarkable antimicrobial activity with allegedly limited systemic side-effects, local antibiotic delivery has been suggested as a method of enhancing clinical outcomes of periodontal therapy. The present systematic review aimed to assess the effect of locally delivered antibiotics during surgical periodontal therapy on CAL gain, PPD reduction, RD changes, BOP scores, GI, PI, and radiographic defect fill. To the best of our knowledge, this is the first review assessing the possible additive benefits of locally delivered antibiotics into the periodontal defects during surgical periodontal therapy of periodontitis induced-defects.

Residual periodontal pockets of 5 mm or more are generally associated with increased risk of periodontal disease progression and tooth loss [42]. Although according to the recent guidelines of the European Federation of Periodontology (EFP), 6 mm was defined as the cut-point for performing periodontal surgery [12], the present review, in line with previous ones [43, 44], still included studies applying periodontal surgical therapy of residual periodontal pockets of 5 mm or more. The rational was to reasonably include the maximum number of RCTs addressing the topic for further strengthening the evidence of the meta-analysis. Although the current review identified a plausible number of nine eligible studies to be included, interpretation of the current review’s results should be done with caution and balanced according to the quality and number of included investigations. The nine investigations included 184 participants with 312 analyzed segments in both groups. Although all experiments were RCTs, three studies showed low [33, 34, 37], five unclear [35, 36, 38–40] and one high risk [41] of bias. Heterogeneity was further notable, regarding study designs (split-mouth or parallel), blinding, number, age, and gender of participants, diagnosis of the periodontal condition requiring a surgical intervention, and clinical attachment level (CAL) gain, probing pocket depth (PPD) reduction, recession depth (RD) changes, gingival index (GI) scores, plaque index (PI) scores, and bleeding on probing (BOP) scores for up to 6 months and more than 6 months of follow-ups for the without (control) and with (test) the adjunctive use of locally delivered antibiotics during surgical periodontal therapy. Study data, number of analyzed segments, mean difference, standard error (SE) of the difference, relative weight (%), pooled effect estimates for different outcomes, and 95% confidence intervals (95% CI) (bold) from random- and fixed-effect meta-analysis are presented. Heterogeneity was assessed by chi-square test and the $I^2$-statistic. Z overall test statistics, $p$ level of significance.
| Time Period | Study/Subgroup | Antibiotic | Mean Difference | Antibiotic | Mean Difference |
|-------------|---------------|------------|----------------|------------|----------------|
| ≤6 months   |               |            |                |            |                |
| CAL         | Akeske 2016   | 1.25       | 0.0158        | 30         | 36 15.9%      | 1.23 (92.15) |
|             | Doweil 2016   | -0.25      | 0.1056        | 18         | 16 12.5%      | 0.22 (91.50) |
|             | Jung 2012     | 0.24       | 0.1384        | 20         | 20 15.8%      | 0.24 (92.90) |
|             | Massena 1999  | 0.07       | 0.1763        | 15         | 16 16.6%      | 0.03 (86.28) |
|             | Rodin 2019    | -0.07      | 0.0135        | 15         | 15 17.3%      | -0.07 (83.01) |
|             | Sandur 2016   | 1.36       | 0.0236        | 12         | 13 15.8%      | 1.36 (92.42) |
|             | Tanaka 2017   | 1.06       | 0.0257        | 20         | 20 15.5%      | 1.06 (92.46) |
| ≥6 to 12 months |               |            |                |            |                |
| PPD         | Lyman 2008    | -0.35      | 0.0477        | 9          | 9 5.8%       | -0.35 (82.82) |
|             | Massena 1999  | 0.22       | 0.0282        | 18         | 18 11.9%      | 0.22 (81.32) |
|             | Needleman 2000| 3.2        | 0.0868        | 18         | 18 11.1%      | 3.20 (83.12) |
|             | Rodin 2016    | 0.07       | 0.0143        | 15         | 15 7.9%       | 0.07 (83.12) |
|             | Tanaka 2017   | 0.09       | 0.0262        | 20         | 20 16.4%      | 0.09 (82.11) |
| ≥6 to 12 months |               |            |                |            |                |
| RD          | Jung 2012     | 0.18       | 0.2405        | 20         | 20 9.8%       | 0.18 (80.60) |
|             | Massena 1996  | 0.18       | 0.1807        | 15         | 15 9.4%       | 0.18 (81.40) |
|             | Massena 1996  | 0.35       | 0.4267        | 9          | 9 9.5%       | 0.35 (86.42) |
| ≥6 to 12 months |               |            |                |            |                |
| GI          | Lyman 2008    | -0.32      | 0.1067        | 9          | 9 34.7%      | -0.32 (99.45) |
|             | Massena 1996  | -0.27      | 0.4415        | 15         | 15 63.9%      | -0.27 (81.40) |
| ≥6 to 12 months |               |            |                |            |                |
| PI          | Akeske 2016   | -0.21      | 0.1072        | 30         | 30 7.9%      | -0.21 (82.40) |
|             | Doweil 2016   | 0.01       | 0.0554        | 18         | 18 69.1%      | 0.01 (85.08) |
|             | Jung 2012     | 0.06       | 0.0988        | 20         | 20 11.0%      | 0.06 (81.17) |
|             | Tanaka 2017   | -0.15      | 0.0385        | 20         | 20 12.3%      | -0.15 (83.01) |
| ≥6 to 12 months |               |            |                |            |                |
| BOP         | Akeske 2016   | -28.69     | 3.2520        | 30         | 30 83.8%      | -28.67 (99.88) |
|             | Jung 2012     | -27.33     | 5.7478        | 20         | 20 16.3%      | -27.33 (85.80) |
|             | Massena 1996  | 50         | 100%          | 50         | 50 100%      | 50 (99.88) |

**Notes:**
- Values represent mean difference with 95% CI.
- For all studies, P > 0.05, indicating no significant difference.
- Values in parentheses indicate the percentage of participants with a positive outcome.
surgical techniques employed, antibiotic agents, their concentrations and delivery methods, and follow-up periods, with the maximum follow-up period being only 12 months in length. Seven out of nine studies were designed as split-mouth interventions, a design that could pose the risk of “carry-across effect”, where drugs delivered at one side could—through the systemic circulation or local diffusion—affect the control site and decrease the observed differences between both control and intervention groups [26, 45]. As none of the included studies investigated this effect, the real effect of antibiotic delivery may actually be higher than reported in this review. Still, this methodological heterogeneity may be interpreted in favor of versatility of antibiotic application during surgical periodontal therapy. Apart from a single study [36], reporting that one participant experienced pain in the site with antibiotic administration, with five participants having pain and unpleasant taste in the control sites 1 week post-operatively, a furcation defect in the control-group failing to close at the end of the follow-up period and the tooth consequently deemed for extraction, none of the included studies reported adverse healing effects. This absence of adverse events during the healing could endorse the locally delivered antibiotics as a safer alternative to systemically administered ones.

Apart from significantly positive effects observed with the locally delivered antibiotics on CAL gain, PPD reduction, GI, and BOP up to 6 months of follow-ups, on longer observation period of more than 6 months, differences in favor of locally delivered antibiotics were only notable for the GI scores. A recent systematic review evaluating the effect of locally delivered antimicrobials in conjunction with non-surgical periodontal therapy [9] reported similar improvements with locally delivered antibiotic application for CAL gain (0.263 mm, 95% CI [0.123; 0.403]) in short-term with no significantly different effects observed for longer-term follow-up (12–60 months) (0.09 mm, 95% CI [−0.253; 0.433]) and a significant POD reduction in short- (0.364 mm, 95% CI [0.236; 0.491]) and long-term (0.190 mm, 95% CI [0.059; 0.321]) follow-ups respectively. A similar systematic review further reported an average CAL gain of 0.27–0.3 mm (range between −0.56 and 1.09 mm) and POD reduction of 0.30–0.48 mm (range between −0.7 and 1.13 mm) with local drug delivery following subgingival mechanical debridement [10]. Yet, the magnitudes of the reported benefits of the locally delivered antimicrobials with non-surgical periodontal therapy for CAL gain and PPD reduction appear smaller than the currently observed results. A possible explanation could rely on the assumption that antibiotics locally delivered during the periodontal surgery into the periodontal defects to be covered by the mucoperiosteal flap could incorporate the antibiotics deeper into the healing tissue, allowing for a sustained antimicrobial effect during the recovery period. In contrast a locally delivered antibiotic into periodontal pockets, following subgingival debridement, depending on the agent and its formulation (solid, gel or solution), could be washed out faster by the gingival crevicular fluid’s flow, rapidly diluting its minimal inhibitory concentration and weakening its effect [8]. Yet, it remains interesting that the plaque scores in all studies were not significantly different between the groups, underlying the importance of self-performed oral hygiene as the most decisive factor in plaque control.

Although the present results demonstrated improvement in periodontal parameters, their clinical significance remains to be evaluated. PPD reduction of 1 mm and CAL gain of 0.5 mm have been defined to represent clinically meaningful values from the periodontal point of view [46]. In this context, WMD of CAL gain observed in the ≤6-month follow-up period (WMD = 0.61 mm) would be considered minimally clinically significant. Still, these outcomes reflect surrogate parameters, which do not fully reproduce true clinical significance. Thus, further studies evaluating long-term tooth survival, cost-benefit aspects, health risks and benefits, and possible complications are required for a founded clinical decision.

Within the limitations of this systematic review and meta-analysis, the findings suggest that the application of adjunctive locally delivered antibiotics during surgical periodontal therapy could enhance CAL gain, PPD reduction, and gingival inflammation, especially ≤6 months post-surgically, with minimal if any adverse side effects. Currently, insufficient

| Table 2 Estimated evidence profile and appraisal of the strength of the recommendation regarding the adjunctive effect of locally delivered antibiotics during periodontal surgery on clinical attachment level gain (≥6 to 12 months; primary outcome) |
|---|---|
| **GRADE criteria** | **Rating** |
| Risk of bias | Serious concern |
| Inconsistency | No (clinical outcome) |
| Indirectness | Yes |
| Imprecision | No clear bias |
| Publication bias | No |
| Other considerations for upgrading the overall rating (magnitude of the effect, dose-dependent relationship, confounders) | Very low |
| Strength of the recommendation based on the quality and body of evidence | Very low |
evidence exists for a clinical recommendation. Future RCTs on the adjunctive usage of antibiotic therapy in conjunction with surgical periodontal therapy need to be conducted, with focus on true endpoints (e.g., tooth survival or oral health outcomes), aiming to identify the ideal agent, its concentration, delivery method (e.g., into membranes or bone grafts), release kinetics, antimicrobial spectrum, and possible effects on the periodontal biological healing events.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00784-021-04056-7.

**Author contribution** S.Y., A.E., and K.F.E. conceived the idea and conducted the systematic review and meta-analysis. K.F.E. and W. E. led the writing.

**Funding** Open Access funding enabled and organized by Project DEAL. The work was supported by the Department of Oral Medicine and Periodontology, Faculty of Dentistry, Cairo University, Egypt.

**Declarations**

**Conflict of interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a notice within the image credit. For any use other than private study or research, permission must be obtained. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Zhang S, Yu N (2000) Arce RM (2020) Periodontal inflammation: integrating genes and dysbiosis. Periodontol 82(1):129–142. https://doi.org/10.1111/prd.12267
2. Slot DE, Valkenburg C, Van der Weijden GAF (2020) Mechanical plaque removal of periodontal maintenance patients: a systematic review and network meta-analysis. J Clin Periodontol 47(Suppl 22):107–124. https://doi.org/10.1111/jcpe.13275
3. Manresa C, Sanz-Miralles EC, Twigg J, Bravo M (2018) Supportive periodontal therapy (SPT) for maintaining the dentition in adults treated for periodontitis. Cochrane Database Syst Rev 1:CD009376. https://doi.org/10.1002/14651858.CD009376.pub2
4. Zhang X, Hu ZX, Zhu XS, Li WJ, Chen J (2020) Treating periodontitis—a systematic review and meta-analysis comparing ultrasonic and manual subgingival scaling at different probing pocket depths. Bmc Oral Health 20(1):176. https://doi.org/10.1186/s12903-020-01117-3
5. Khatri S, Kumbargere Nagraj S, Arora A, Easchampati P, Kusum CK, Bhat KG, Johnson TM, Lodi G (2020) Adjunctive systemic antimicrobials for the non-surgical treatment of periodontitis. Cochrane Database Syst Rev 11:CD012568. https://doi.org/10.1002/14651858.CD012568.pub2
6. Zandbergen D, Slot DE, Niederman R, Van der Weijden FA (2016) The concomitant administration of systemic amoxicillin and metronidazole compared to scaling and root planing alone in treating periodontitis: a systematic review. Bmc Oral Health 16:27. https://doi.org/10.1186/s12903-015-0123-6
7. Teughels W, Feres M, Oud V, Martin C, Matesanz P, Herrera D (2020) Adjunctive effect of systemic antimicrobials in periodontitis therapy: a systematic review and meta-analysis. J Clin Periodontol 47(Suppl 22):257–281. https://doi.org/10.1111/jcpe.13264
8. Wang CY, Yang YH, Li H, Lin PY, Su YT, Kuo MY, Tu YK (2020) Adjunctive local treatments for patients with residual pockets during supportive periodontal care: a systematic review and network meta-analysis. J Clin Periodontol 47(12):1496–1510. https://doi.org/10.1111/jcpe.13397
9. Herrera D, Matesanz P, Martin C, Oud V, Feres M, Teughels W (2020) Adjunctive effect of locally delivered antimicrobials in periodontitis therapy: a systematic review and meta-analysis. J Clin Periodontol 47(Suppl 22):239–256. https://doi.org/10.1111/jcpe.13230
10. Tan OL, Safii SH, Razali M (2020) Clinical efficacy of single application local drug delivery and adjunctive agents in nonsurgical periodontal therapy: a systematic review and network meta-analysis. Pharmaceutics 12(11). https://doi.org/10.3390/pharmaceutics12111086
11. Nibali L, Koidou VP, Nieri M, Barbato L, Pagliaro U, Cairo F (2020) Regenerative surgery versus access flap for the treatment of intra-bony periodontal defects: a systematic review and meta-analysis. J Clin Periodontol 47(Suppl 22):320–351. https://doi.org/10.1111/jcpe.13237
12. Sanz M, Herrera D, Kebschull M, Chapelle I, Jepsen S, Beglundh T, Sculean A, Tonetti MS, Participants EFPW, Methodological C (2020) Treatment of stage I-III periodontitis—the EFP S3 level clinical practice guideline. J Clin Periodontol 47(Suppl 22):4–60. https://doi.org/10.1111/jcpe.13290
13. Reikholz P, Rollke L, Schachner B, Wohlfell M, Dannewitz B, Kaltschmit J, Krieger JK, Kriger DM, Reitmeir P, Kim TS (2014) Enamel matrix derivative in propylene glycol alginate for treatment of infrabony defects with or without systemic doxycycline: 12- and 24-month results. J Periodontol 85(5):669–675. https://doi.org/10.1902/jop.2013.130290
14. Pietruska M, Dolinska E, Milewski R, Sculean A (2021) Effect of systemic antibiotics on the outcomes of regenerative periodontal surgery in intrabony defects: a randomized, controlled, clinical study. Clin Oral Investig 25(5):2959–2968. https://doi.org/10.1007/s00784-020-03616-7
15. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 10:CD000142. https://doi.org/10.1002/14651858.CD000142
16. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097
17. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan—a web and mobile app for systematic reviews. Syst Rev 5(1):210. https://doi.org/10.1186/s13643-016-0384-4
18. McHugh ML (2012) Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 22(3):276–282
19. Lang NP, Adler R, Joss A, Nyman S (1990) Absence of bleeding on probing. An indicator of periodontal stability. J Clin Periodontol 17(10):714–721. https://doi.org/10.1111/j.1600-051x.1990.tb01059.x
20. Loe H (1967) The Gingival Index, the Plaque Index and the retention index systems. J Periodontol 38(6):Suppl:610–Suppl:616. https://doi.org/10.1902/jop.1967.38.6.610

21. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Bouton I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernan MA, Hopewell S, Hrobjartsson A, Junqueira DR, Juni P, Kirkham JJ, Lasserson T, Li T, McAlenian A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:i4898. https://doi.org/10.1136/bmj.i4898

22. Ferguson D, Aaron SD, Guyatt G, Hebert P (2002) Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ 325(7365):652–654. https://doi.org/10.1136/bmj.325.7365.652

23. Diaz-Faes L, Fernandez-Somoano A, Magan-Fernandez A, Mesa F (2020) Efficacy of regenerative therapy in aggressive periodontitis: a systematic review and meta-analysis of randomised controlled trials. Clin Oral Investig 24(4):1369–1378. https://doi.org/10.1007/s00784-020-02327-0

24. Sgolastra F, Petruzzi A, Ciarrocchi C, Masci C, Spadaro A (2021) Adjunctive systemic antimicrobials in the treatment of chronic periodontitis: a systematic review and network meta-analysis. J Periodontal Res 56(2):236–248. https://doi.org/10.1111/jper.12821

25. Follmann D, Elliott P, Suh I, Cutler J (1992) Variance imputation in meta-analyses: a critical evaluation. J Clin Epidemiol 45(7):769–773. https://doi.org/10.1016/0895-4356(92)90054-q

26. Lesaffre E, Philstrom B, Needelman I, Worthington H (2009) The design and analysis of split-mouth studies: what statisticians and clinicians should know. Stat Med 28(28):3470–3482. https://doi.org/10.1002/sim.3634

27. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N (2006) Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 59(1):7–10. https://doi.org/10.1016/j.clinepi.2005.06.006

28. Murad MH, Montori VM, Ioannidis JPA, Guyatt G, Rennie D, Meade MO (2015) Chapter 25.1: fixed-effects and random-effects models, users’ guide to the medical literature. A manual for evidence-based clinical practice, 3rd edn. McGraw-Hill, New York

29. Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Statistics in medicine 21(11):1539–1558. https://doi.org/10.1002/sim.1186

30. Deeks JJ, Higgins JP, Altman DG, Group obotCSM (2019) Analysing data and undertaking meta-analyses. In: Cochrane handbook for systematic reviews of interventions. pp 241–284. https://doi.org/10.1002/9781119536604.ch10

31. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634. https://doi.org/10.1136/bmj.315.7109.629

32. Alonso-Coello P, Schunemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, Treweek S, Mustafa RA, Rada G, Rosenbaum S, Morelli A, Guyatt GH, Oxman AD (2016) GRADE evidence to decision (EiD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ 353:i2016. https://doi.org/10.1136/bmj.i2016

33. Lyons LC, Weltman RL, Moretti AJ, Trejo PM (2008) Regeneration of degree ii furcation defects with a 4% doxycycline hyclate bioabsorbable barrier. J Periodontol 79(1):72–79. https://doi.org/10.1902/jop.2008.070161

34. Needelman IG, Collins AM, Moles DR (2000) Periodontal flap surgery with 25% metronidazole gel. (1). Clinical outcomes. J Clin Periodontol 27(3):187–192. https://doi.org/10.1034/j.1600-051x.2000.027003187.x

35. Abbas S, Mahendra J, Ari G (2016) Minocycline ointment as a local drug delivery in the treatment of generalized chronic periodontitis - a clinical study. J Clin Diagn Res 10(6):ZC15–ZC19. https://doi.org/10.3774/jcdr.2016.9468.7930

36. Dowell P, al-Arayed F, Adam S, Moran J (1995) A comparative clinical study: the use of human type I collagen with and without the addition of metronidazole in the GTR method of treatment of periodontal disease. J Clin Periodontol 22(7):543–549. https://doi.org/10.1111/j.1600-051x.1995.tb00803.x

37. Jung DY, Park JC, Kim YT, Yon JY, Im GI, Kim BS, Choi SH, Cho KS, Kim CS (2012) The clinical effect of locally delivered minocycline in association with flap surgery for the treatment of chronic severe periodontitis: a split-mouth design. J Clin Periodontol 39(8):753–759. https://doi.org/10.1111/j.1600-051x.2012.01908.x

38. Masters LB, Mellonig JT, Brunsvold MA, Numnikoski PV (1996) A clinical evaluation of demineralized freeze-dried bone allograft in combination with tetracycline in the treatment of periodontal osseous defects. J Periodontol 67(8):770–781. https://doi.org/10.1902/jop.1996.67.8.770

39. Reddy NYV, Deepika PC, Venkatesh MP, Rajeshwari KG (2016) Evaluation of moxifloxacin-hydroxyapatite composite graft in the regeneration of intrabony defects: a clinical, radiographic, and microbiological study. Contemp Clin Dent 7(3):357–365. https://doi.org/10.4103/0976-237X.188564

40. Sander L, Frandsen EV, Ambjerg D, Warrer K, Karring T (1994) Effect of local metronidazole application on periodontal healing following guided tissue regeneration. Clinical findings. J Periodontol 65(10):914–920. https://doi.org/10.1902/jop.1994.65.10.914

41. Taneya N, Kudva P, Goswamy M, Bhat GK, Kudva HPJJoID (2017) A comparative evaluation of platelet-rich fibrin with metronidazole and platelet-rich fibrin alone in the treatment of intrabony periodontal defects: A clinical and radiographical study. 7 (3):101

42. Matuliene G, Pjetursson BE, Salvi GE, Schmidlin K, Bragger U, Zwahlen M, Lang NP (2008) Influence of residual pockets on progression of periodontitis and tooth loss: results after 11 years of maintenance. J Clin Periodontol 35(8):685–695. https://doi.org/10.1111/j.1600-051x.2008.01245.x

43. Polak D, Wilensky A, Antonoglou GN, Shapiro L, Goldstein M, Martin C (2020) The efficacy of pocket elimination/reduction compared to access flap surgery: a systematic review and meta-analysis. J Clin Periodontol 47(Suppl 22):303–319. https://doi.org/10.1111/jcpe.13246

44. Ferrarotti F, Giuradi M, Citterio F, Fratini A, Gualiani G, Piccoli GM, Mariani GM, Romano F, Aimmetti M (2020) Pocket elimination after osseous resective surgery: a systematic review and meta-analysis. J Clin Periodontol 47(6):756–767. https://doi.org/10.1111/jcpe.13281

45. Hujcic CPP, DeRouen TA (1992) Validity issues in split-mouth trials. J Clin Periodontol 19(9 Pt 1):625–627. https://doi.org/10.1902/jopr.1992.tb01709.x

46. Mon-Son-Hing M, Laupacis A, O'Rourke K, Molnar FJ, Mahon J, Chan KBY, Wells G (2009) Determination of the clinical importance of study results - a review. J Gen Intern Med 17(6):469–476. https://doi.org/10.1004/jjim.1525-1497.2002.11111.x

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.